Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a leading clinical-stage biopharmaceutical firm engaged
in the development of immunotherapies for cancer and effective stem
cell therapies for degenerative diseases, today announced the
establishment of a strategic partnership with Thermo Fisher
Scientific (China) Ltd. (Thermo Fisher) to build a joint Cell
Therapy Technology Innovation and Application Center (Center) at
CBMG’s newly opened Shanghai Zhangjiang GMP facility. The
Center is named “CBMG-Thermo Fisher Scientific Joint Innovation
& Application Center.” The partnership focuses on the research
and development of an automated cell therapy manufacturing system.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/99a643ad-27fa-481d-98a0-45fd1421c1b3
“Break-through cell therapy technology such as
CAR-T provides unprecedented medical needs to cancer patients, yet
the successful commercialization of this technology will require
robust logistics, manufacturing and complex management systems,”
commented Tony (Bizuo) Liu, CEO of CBMG. “When we combine Thermo
Fisher's strengths in biopharmaceutical products and manufacturing
quality control processes with CBMG’s vertically integrated cell
therapy manufacturing system, we believe we can further increase
productivity, reduce cost, improve batch stability, reduce
variability and institutionalize the Chemistry, Manufacturing, and
Controls (CMC) processes, which we believe will help to address
some of the primary logistical challenges faced by the CAR-T cell
therapy industry. We are optimistic that this partnership will not
only bring mutual benefit to CBMG and Thermo Fisher, but also to
the cell therapy industry sector as a whole.”
“This cooperation demonstrates our commitment to
China. As a world leader in serving science, Thermo Fisher seeks to
provide total solutions for cell therapy research, development, and
manufacturing. We believe this will help to accelerate the
development of the cell therapy industry in China. Based on our
broad product portfolio, Thermo Fisher has developed outstanding
capabilities in global CAR-T manufacturing, including our Cell
Therapy Systems (CTS™) Dynabeads™ technology in the first
FDA-approved cell therapy,” said Gianluca Pettiti, President of
Thermo Fisher China. “We look forward to this strategic partnership
and the benefits that the Joint Innovation and Application Center
will provide to a vast Chinese patient population.”
CBMG’s new Zhangjiang facility, together with an
expanded Wuxi and Beijing GMP facilities combined, comprises 70,000
square feet for development and production. This will enable CBMG
to conduct simultaneous clinical trials for multiple CAR-T and stem
cell product candidates. At full production volumes, these
facilities could support treating 10,000 cancer patients and 10,000
Knee Osteoarthritis patients per year. The Company’s combined GMP
expansion will enable scaled-up supply for current and future CAR-T
clinical trials and streamline efficiency from R&D into
manufacturing of CAR-T cells for clinical use, IND filings and
future commercialization. The Company currently has ongoing CAR-T
Phase I clinical trials in China; CARD-1 for Diffuse Large B-cell
Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL) and CALL-1 for
adult Acute Lymphoblastic Leukemia (ALL), utilizing CBMG’s
proprietary and optimized CD19 construct.
About Cellular Biomedicine Group Cellular
Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of cancer and degenerative diseases. We conduct
immuno-oncology and stem cell clinical trials in China using
products from our integrated GMP laboratory. Our GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. To learn more about CBMG, please visit
www.cellbiomedgroup.com.
About Thermo Fisher Scientific Thermo Fisher
Scientific Inc. is the world leader in serving science, with
revenues of more than $20 billion and approximately 65,000
employees globally. Our mission is to enable our customers to make
the world healthier, cleaner and safer. We help our customers
accelerate life sciences research, solve complex analytical
challenges, improve patient diagnostics, deliver medicines to
market and increase laboratory productivity. Through our premier
brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher
Scientific and Unity Lab Services – we offer an unmatched
combination of innovative technologies, purchasing convenience and
comprehensive services. For more information, please visit
www.thermofisher.com.
About Thermo Fisher Scientific China Thermo
Fisher Scientific (China) Co., Ltd has been operating in China for
over 35 years. Headquartered in Shanghai, Thermo Fisher Scientific
China has branch offices in Beijing, Guangzhou, Hong Kong, Chengdu,
Shenyang, Xian, Nanjing, Wuhan, Kunming and other cities with
around 4,000 employees. Our products mainly include analytical
instruments, laboratory equipment, chemical reagents, consumables,
software and more; providing comprehensive laboratory solutions and
serving customers across various industries. In order to meet the
local needs in China, we have established 6 manufacturing sites in
Shanghai, Beijing and Suzhou respectively. We also have 5
application centers across the country, which bring world-class
technology and products with application development and training
services to local customers. Lastly, we have the China Innovation
Center in Shanghai, which develops products according to local
demands with global advanced technology. We have a nationwide
maintenance network and China service training team, including over
2,000 professionals directly providing services for customers. We
are committed to enabling our customers to make the world
healthier, cleaner and safer. For more information, please visit
www.thermofisher.com.
Forward-Looking Statements This press release
contains forward-looking statements—including descriptions of
plans, strategies, trends, specific activities, investments and
other non-historical facts—as defined by the Private Securities
Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking information is inherently
uncertain, and actual results could differ materially from those
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy
(including the devaluation of the RMB by China in August 2015), and
other risks detailed in CBMG’s reports filed with the Securities
and Exchange Commission, quarterly reports on form 10-Q, current
reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
“may,” “will,” “expects,” “plans,” “intends,” “estimates,”
“potential,” “continue” or similar terms or their negations.
Although CBMG believes the expectations reflected in the
forward-looking statements are reasonable, they cannot guarantee
that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts: Sarah Kelly Director of Corporate
Communications, CBMG+1 650 566-5064+86 21 5406 9990
sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024